Tag: biopsies

Breakthroughs in Non-invasive Liver Testing Promise Fewer Biopsies

Two international studies have show that non-invasive tests can accurately diagnose and measure liver disease severity, reducing the need for biopsy. Published in The Lancet and Nature Medicine, the studies form part of the LITMUS programme, the largest international effort to evaluate diagnostic tools for metabolic dysfunction-associated steatotic liver disease (MASLD), including its more severe form, metabolic dysfunction-associated steatohepatitis (MASH).

To date, liver biopsy has been considered the reference standard for definitively distinguishing MASLD from active MASH with fibrosis, but its invasive nature carries procedural risks and it is resource-intensive. The diagnostic reliability of liver biopsy is limited by sampling error and by variability in tissue adequacy, with interobserver variability adding to challenges in histological interpretation.

The main LITMUS Study, published in The Lancet, assessed blood tests and ultrasound-based liver stiffness measurements in more than 1500 patients – the largest international study of its kind.

The companion LITMUS Imaging Study, published in Nature Medicine, examined advanced MRI and elastography techniques in more than 350 patients.

Together, these two studies give us the most complete picture yet of which diagnostic tests work for liver disease, and how to combine them into a pathway health systems can easily implement

Professor Quentin Anstee

New benchmark in liver disease diagnosis

Professor Quentin Anstee, Ruth & Lionel Jacobson Chair in Personalised Medicine at Newcastle University, and Honorary Consultant Hepatologist at Newcastle Hospitals NHS Foundation Trust, is joint senior author of both studies and the LITMUS consortium coordinator.

He said: “Together, these two studies give us the most complete picture yet of which diagnostic tests work for liver disease, and how to combine them into a pathway health systems can easily implement.

“For advanced liver scarring and cirrhosis, we now have tools good enough to use with real confidence. Detecting active liver inflammation remains more challenging, but promising non-invasive tests are becoming available.”

MASLD affects up to one in three adults worldwide and as many as seven in 10 people living with obesity or type 2 diabetes.

As the first licensed drug treatments for MASH enter clinical practice, there is growing demand for accurate, non-invasive ways to diagnose and monitor disease.

Together, the studies assessed dozens of blood, imaging and elastography-based biomarkers – covering both state-of-the-art and routine diagnostic tests that are already used by doctors – comparing their accuracy to liver biopsy, read by expert pathologists.

The findings provide robust, prospective and independent evidence from large multinational patient cohorts, offering what researchers believe are the most realistic benchmarks yet for non-invasive liver disease testing.

The key findings of the studies are:

  • For advanced liver fibrosis and cirrhosis, the SOMAScan proteomic panel, MR elastography (MRE) and FibroScan-based elastography tools, including the Agile 3+ score, delivered the highest levels of diagnostic accuracy.
  • The ELF and ADAPT blood tests also exceeded predefined performance thresholds for detecting cirrhosis.
  • For identifying “at-risk MASH” – the group targeted in most clinical trials – only the SOMAScan panel met the predefined accuracy threshold.
  • A simple and inexpensive gamma-GT blood test outperformed the widely used FIB-4 score as a first-line assessment tool and could be followed by FibroScan or ELF testing to confirm disease severity in routine care.

Targeting the right patients for referral to specialist liver care

The findings support a simplified diagnostic pathway that, after further validation, could be adopted across healthcare systems: use gamma-GT as an initial screening test, followed by ELF or FibroScan for patients requiring further assessment, with advanced imaging reserved for specialist care.

This approach could help more patients receive an accurate diagnosis without undergoing an invasive liver biopsy while ensuring specialist resources are targeted where they are most needed.

The findings also have important implications for MASH clinical trials.

Because regulators require confirmation of “at-risk MASH” for enrolment in late-stage studies, liver biopsy is likely to remain necessary for now. However, the strong performance of SOMAScan highlights its potential for future adoption.

The LITMUS Imaging Study also demonstrated that elastography techniques performed well for detecting advanced fibrosis and cirrhosis, with MRE outperforming FibroScan-based liver stiffness measurements.

Reference:

Non-invasive tests in Metabolic-dysfunction Associated Steatotic Liver Disease: The prospective, multi-centre LITMUS Study. The Lancet, 2026. Vali et al. DOI: 10.1016/S0140-6736(26)01145-1 

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD. Nature Medicine, 2026. Pavlides et al. DOI: 10.1038/s41591-026-04496-2

Source: Newcastle University

A New Alternative to Skin Biopsies

Source: Pixabay

A new ‘virtual histology’ technology being developed by researchers could replace many skin tissue biopsies. The technology is detailed in Light: Science & Applications. 

Histology is the microscopic study of tissues and organs through sectioning, staining, and examining those sections under a microscope. Often called microscopic anatomy and histochemistry, histology allows for the visualisation of tissue structure and characteristic changes the tissue may have undergone.

“This process bypasses several standard steps typically used for diagnosis – including skin biopsy, tissue fixation, processing, sectioning and histochemical staining. Images appear like biopsied, histochemically stained skin sections imaged on microscope slides,” said the study’s senior author, Aydogan Ozcan, Chancellor’s Professor and Volgenau Chair for Engineering Innovation of the Electrical and Computer Engineering Department at UCLA Samueli.

The technology may enable rapid diagnosis of malignant skin tumours, reducing unnecessary invasive skin biopsies and allowing skin cancer diagnosis at an earlier stage. This technology had only previously been applied to microscopy slides of unstained tissue, acquired through a biopsy. This is the first time virtual histology has been applied to intact, unbiopsied tissue.

“The current standard for diagnosing skin diseases, including skin cancer, relies on invasive biopsy and histopathological evaluation. For patients, this often leads to unnecessary biopsies and scars as well as multiple visits to doctors. It also can be costly for patients and the health care system,” said Dr Philip Scumpia, assistant professor of dermatology and dermatopathology at the David Geffen School of Medicine at UCLA and the West Los Angeles Veterans Affairs Hospital and a member of the UCLA Jonsson Comprehensive Cancer Center. “Our approach potentially offers a biopsy-free solution, providing images of skin structure with cellular-level resolution.”

The research team, led by Ozcan, Scumpia and Dr. Gennady Rubinstein, a dermatologist at the Dermatology & Laser Centre in Los Angeles, created a deep-learning framework to transform images of intact skin acquired by an emerging noninvasive optical technology, reflectance confocal microscopy (RCM), into a format that is user-friendly for dermatologists and pathologists. Analysing RCM images requires special training because they are in black and white, and unlike standard histology, they lack nuclear features of cells.

“I was surprised to see how easy it is for this virtual staining technology to transform the images into ones that I typically see of skin biopsies that are processed using traditional chemical fixation and tissue staining under a microscope,” Dr Scumpia said.

The researchers trained a neural network to rapidly transform RCM images of unstained skin into virtually stained 3D images like the H&E (haematoxylin and eosin) images familiar to dermatologists and dermatopathologists.

“This framework can perform virtual histology on a variety of skin conditions, including basal cell carcinoma. It also provides detailed 3D images of several skin layers,” said Ozcan. “In our studies, the virtually stained images showed similar color contrast and spatial features found in traditionally stained microscopic images of biopsied tissue. This approach may allow diagnosticians to see the overall histological features of intact skin without invasive skin biopsies or the time-consuming work of chemical processing and labeling of tissue.”

“The only tool currently used in clinics to help a dermatologist are dermatoscopes, which magnify skin and polarise light. At best, they can help a dermatologist pick up patterns,” said Rubinstein, who also uses reflectance confocal microscopes in clinic.

The authors said there is a way to go before clinical use, but they aim to introduce the technology at various scales alongside other optical-imaging systems. Once the neural network is “trained,” with many tissue samples and the use of powerful graphics processing units (GPUs), it will be able to run on a computer or network, enabling rapid transformation from a standard image to a virtual histology image.

This technology could usher in a new age of “digital dermatology” and change how dermatology is practised. Additionally, the research team will see if this artificial intelligence platform can work with other AI technologies to look for patterns and further aid in clinical diagnosis.

Source: UCLA